Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Shares Outstanding (Diluted Average): 2023-2024

Historic Shares Outstanding (Diluted Average) for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $73.9 million.

  • Monte Rosa Therapeutics' Shares Outstanding (Diluted Average) rose 1.14% to $82.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.9 million, marking a year-over-year increase of 1.14%. This contributed to the annual value of $73.9 million for FY2024, which is 43.80% up from last year.
  • As of FY2024, Monte Rosa Therapeutics' Shares Outstanding (Diluted Average) stood at $73.9 million, which was up 43.80% from $51.4 million recorded in FY2023.
  • In the past 5 years, Monte Rosa Therapeutics' Shares Outstanding (Diluted Average) registered a high of $73.9 million during FY2024, and its lowest value of $51.4 million during FY2023.
  • Moreover, its 2-year median value for Shares Outstanding (Diluted Average) was $62.7 million (2023), whereas its average is $62.7 million.
  • Data for Monte Rosa Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY soared of 43.80% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Monte Rosa Therapeutics' Shares Outstanding (Diluted Average) stood at $51.4 million in 2023, then skyrocketed by 43.80% to $73.9 million in 2024.